Phase I trial of IMO 9200 in volunteers

Trial Profile

Phase I trial of IMO 9200 in volunteers

Phase of Trial: Phase I

Latest Information Update: 18 May 2015

At a glance

  • Drugs IMO 9200 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 18 May 2015 Results published in the Idera Pharmaceuticals Media Release.
    • 18 May 2015 Status changed from recruiting to completed, according to an Idera Pharmaceuticals media release.
    • 07 Nov 2014 Idera Pharmaceuticals expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top